STOCKWATCH
·
Pharmaceuticals
Quarterly Result29 May 2025, 11:13 am

FDC Ltd Crosses 22,000 Crore Revenue Mark in FY25, Despite 25.6% Decline in Export Formulation Business

AI Summary

FDC Limited, a manufacturer and exporter of foods, drugs, and chemicals, reported its financial results for the quarter and year ended March 31, 2025. The company's revenue grew by 8.5% to reach 22,108 crore, with the India Formulations business contributing 84% of sales and growing by 14.4% YoY. The Export Formulation business, however, reported a decline of 25.6% YoY primarily due to lower sales in the US market and a few ROW markets due to regulatory issues. The regulatory issues have been addressed, and the management believes the business will return to normal in the coming financial year. The profitability was impacted by the drop in the Export formulation business, reduction in price of Electral due to NLEM price revision announcement during QIFY25, and higher employee costs. The company was the 2nd fastest-growing company among the Top 25 companies, supported mainly by flagship brand Electral, Zifi and Enerzal.

Key Highlights

  • FDC Ltd crossed the 22,000 crore revenue mark in FY25, growing 8.5% to reach 22,108 crore.
  • India Formulations business contributed 84% of sales and grew 14.4% YoY.
  • Export Formulation business declined by 25.6% YoY primarily due to lower sales in US market and few ROW markets.
  • Regulatory issues in US market have been addressed and management expects business to return to normal in coming financial year.
  • Company was the 2nd fastest growing company among Top 25 companies, supported mainly by flagship brand Electral, Zifi and Enerzal.
FDC
Pharmaceuticals
FDC LTD.

Price Impact